Compare · AZN vs KRRO
AZN vs KRRO
Side-by-side comparison of AstraZeneca PLC (AZN) and Korro Bio Inc. (KRRO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and KRRO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 1482.5x KRRO ($176.7M).
- Over the past year, AZN is down 10.3% and KRRO is down 7.5% - KRRO leads by 2.8 points.
- AZN has been more active in the news (12 items in the past 4 weeks vs 6 for KRRO).
- Both have 25 recent analyst ratings on file.
- Company
- AstraZeneca PLC
- Korro Bio Inc.
- Price
- -
- -
- Market cap
- $261.92B
- $176.7M
- 1M return
- -5.56%
- +15.23%
- 1Y return
- -10.32%
- -7.54%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2019
- News (4w)
- 12
- 6
- Recent ratings
- 25
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest KRRO
- Chief Scientific Officer Vincent Loic A was granted 7,500 shares, increasing direct ownership by 41% to 25,797 units (SEC Form 4)
- Senior Vice President, Finance Dolan Oliver was granted 5,500 shares, increasing direct ownership by 30% to 23,599 units (SEC Form 4)
- General Counsel Cerio Jeffrey was granted 6,500 shares, increasing direct ownership by 18% to 41,793 units (SEC Form 4)
- Chief Operating Officer Chappell Todd was granted 7,500 shares, increasing direct ownership by 44% to 24,464 units (SEC Form 4)
- Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Formela Jean Francois sold $1,542,970 worth of shares (110,023 units at $14.02) as part of a pre-agreed trading plan (SEC Form 4)
- Director Formela Jean Francois sold $2,458,582 worth of shares (171,405 units at $14.34) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Chappell Todd sold $34,309 worth of shares (3,168 units at $10.83), decreasing direct ownership by 16% to 16,964 units (SEC Form 4) to satisfy withholding tax
- Chief Scientific Officer Vincent Loic A sold $37,017 worth of shares (3,418 units at $10.83), decreasing direct ownership by 16% to 18,297 units (SEC Form 4) (withholding obligation)
- General Counsel Cerio Jeffrey sold $71,575 worth of shares (6,609 units at $10.83), decreasing direct ownership by 16% to 35,293 units (SEC Form 4) (tax liability)